Gene Therapy for ALS—A Perspective - Sorbonne Université Access content directly
Journal Articles International Journal of Molecular Sciences Year : 2019

Gene Therapy for ALS—A Perspective

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease (MND) with no cure. Recent advances in gene therapy open a new perspective to treat this disorder-particularly for the characterized genetic forms. Gene therapy approaches, involving the delivery of antisense oligonucleotides into the central nervous system (CNS) are being tested in clinical trials for patients with mutations in SOD1 or C9orf72 genes. Viral vectors can be used to deliver therapeutic sequences to stably transduce motor neurons in the CNS. Vectors derived from adeno-associated virus (AAV), can efficiently target genes and have been tested in several pre-clinical settings with promising outcomes. Recently, the Food and Drug Administration (FDA) approved Zolgensma, an AAV-mediated treatment for another MND-the infant form of spinal muscular atrophy. Given the accelerated progress in gene therapy, it is potentially a promising avenue to develop an efficient and safe cure for ALS.
Fichier principal
Vignette du fichier
ijms-20-04388-v2.pdf (1.3 Mo) Télécharger le fichier
Origin Publication funded by an institution
Loading...

Dates and versions

hal-02343415 , version 1 (02-11-2019)

Identifiers

Cite

Marisa Cappella, Chiara Ciotti, Mathilde Cohen-Tannoudji, Maria Grazia Biferi. Gene Therapy for ALS—A Perspective. International Journal of Molecular Sciences, 2019, 20 (18), pp.4388. ⟨10.3390/ijms20184388⟩. ⟨hal-02343415⟩
110 View
99 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More